[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibrosis-of-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibrosis-of-liver":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,76,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100620601","assessing-signatures-for-fibrosis-detection-in-chronic-liver-disease-a-step-beyond-conventional-biomarkers-100620601",false,"NCT07359742","Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers","Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers.","Inclusion Criteria:\n\n* ≥18y\n* Chronic liver disease: alcohol, metabolic dysfunction associated steatotic liver disease, viral hepatitis, autoimmune hepatitis, cholestatic liver disease and hemochromatosis\n\nExclusion Criteria:\n\n* \\\u003C18y\n* Acute hepatitis\n* Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"NA","Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development. When hepatocytes are damaged, HSCs undergo myofibroblast differentiation, transitioning into an activated state. So far, no efficient biomarkers can estimate the degree of HSC activation or reversal across all aetiologies of CLD, although this could be a more sensitive marker than fibrosis measurement which is secondary to HSC activation. This study aims to correlate biomarkers to the fibrosis stage in a larger cohort of patients with CLD across all aetiologies.",[26,27],"Chronic Liver Disease (CLD)","Fibrosis of Liver",[29,30],"chronic liver disease","fibrosis","RECRUITING","2026-04-30",{"date":34,"type":35},"2026-05-06","ACTUAL",{"date":37,"type":20},"2026-05",{"date":39,"type":20},"2028-01",{"name":41,"class":42},"Universitair Ziekenhuis Brussel","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100613763","screening-for-masld-related-advanced-fibrosis-in-type-2-diabetes-100613763","NCT07270822","Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes","Implementation of a Systematic Screening for MASLD-related Advanced fibrosiS for Patients With Type 2 Diabetes folLoweD by DIABetologists","MASLD-DIAB","Inclusion Criteria:\n\n* Adult patient, male or female\n* Type 2 diabetic patient, followed by a diabetologist in private practice participating in the study\n* Patient affiliated to a French or European healthcare insurance\n* Patient who agrees to be included in the study and who signs the informed consent form\n\nExclusion Criteria:\n\n* Evidence of advanced fibrosis (F3 or F4 fibrosis based on the results from previous liver biopsy F3 ou F4 or evidence of cirrhosis).\n* Evidence of other causes of chronic liver disease\n* Patient who does not understand French\u002F is unable to give consent,\n* Patient already included in a trial who may interfere with the study\n* The subject is a pregnant or nursing female\n* Minor patient\n* Patient deprived of liberty,\n* Patient admitted to a health or social establishment for purposes other than research\n* Mentally unbalanced patients, under supervision or guardianship,\n* Patient undergoing psychiatric care\n* Patient not affiliated to a healthcare insurance plan\n* Patient already included in this screening program in the previous 12 months",{"count":53,"type":20},1714,[23],"Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of progression to advanced fibrosis (AF) (fibrosis stage F3 or cirrhosis F4). Screening for AF is justified because it is associated with an increased risk of overall, hepatic, and cardiovascular mortality and therefore constitutes a public health issue.\n\nPatients with type 2 diabetes (T2D) are identified as a priority target for screening because they are at high risk of AF related to MASLD. The recommendations of the French Association for the Study of the Liver 2020 (afef.asso.fr), the European Association for the Study of the Liver (2024), the American Association of Clinical Endocrinology (2022), and the American Association of Diabetes (2025) all recommend a two-step screening process involving the FIB-4 biological score, followed by transient elastography (TE) if the FIB-4 score is \\> or = 1.30. Finally, if the TE is ≥8 kPa, the patient is considered to be at intermediate\u002Fhigh risk of AF requiring specialized care to confirm the diagnosis and implement appropriate management, including semi-annual screening for hepatocellular carcinoma in cases of cirrhosis Despite these recommendations, their application in clinical practice remains difficult and requires multidisciplinary collaboration between diabetologists and hepatologists, and between community and hospital sectors, particularly to access TE measures.\n\nSince 2018, the Lyon Sud diabetes department (Hospices Civils de Lyon) has implemented an in-hospital AF screening program using TE for T2D patients. However, this screening by private diabetologists has not yet been implemented, mainly due to the lack of a standardized care pathway and difficulty in accessing TE measurements.\n\nHYPOTHESIS The implementation of systematic and standardized AF screening in private diabetes practices, in two stages and using ET in diabetes care in accordance with recommendations, would significantly increase the identification of patients with AF and thus improve their access to specialized services and appropriate care.",[57,27],"Steatotic Liver Disease",[59,60,61,62,63,64],"Metabolic dysfunction-associated steatotic liver disease","hepatic transient elastography","hepatic fibrosis","type 2 diabetes mellitus","screening","non-invasive tests","NOT_YET_RECRUITING","2026-04-02",{"date":68,"type":35},"2026-04-03",{"date":70,"type":20},"2026-05-01",{"date":72,"type":20},"2029-03-01",{"name":74,"class":42},"Hospices Civils de Lyon",10,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100616416","improving-liver-fibrosis-diagnosis-in-primary-care-using-fibrox-ai-100616416","NCT07305324","Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI","Validation of an AI Tool for Improving MASLD Advanced Liver Fibrosis Diagnosis in Primary Care: A Provider-Level Crossover Randomized Controlled Trial Pilot","Inclusion Criteria:\n\n* Licensed primary care providers (MD, DO, NP, or PA)\n* Currently practicing in adult primary care (≥0.5 Full-Time Equivalent)\n* Affiliated with one of the participating clinics (academic, community, or Federally Qualified Health Center)\n* Willing and able to participate in simulated electronic health record (EHR)-based case reviews\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Providers not actively practicing in adult primary care\n* Providers with less than 0.5 FTE in clinical practice\n* Prior involvement in the development or validation of the FibroX tool\n* Inability to complete both simulation periods due to scheduling or other constraints",{"count":84,"type":20},40,[23],"The goal of this clinical trial is to learn whether an artificial intelligence (AI) tool called FibroX can help primary care providers better diagnose significant liver fibrosis (≥F2) and clinically significant portal hypertension in adults with metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nThe main questions it aims to answer are:\n\n* Can FibroX improve the accuracy of diagnosing significant liver fibrosis (≥F2) and clinically significant portal hypertension compared to usual care?\n* Is FibroX easy to use and acceptable to primary care providers in simulated clinical settings?\n* Do providers trust FibroX as a decision-support tool?\n\nResearchers will compare FibroX-assisted care to usual care to see if FibroX improves diagnostic accuracy, provider trust, and supports better decision-making.\n\nParticipants will:\n\n* Be primary care providers (MDs, DOs, NPs, PAs) from diverse clinics\n* Review simulated patient cases with MASLD risk factors\n* Use either usual care tools (standard labs and optional FIB-4 calculator) or FibroX (AI-generated risk score, triage band, and explainability panel)\n* Make diagnostic and referral decisions for each case\n* Complete surveys on usability, trust in AI, confidence, and cognitive workload\n\nThis study will help determine whether FibroX can be integrated into real-world primary care workflows to support earlier and more accurate detection of liver fibrosis and portal hypertension, potentially reducing missed diagnoses, unnecessary referrals, and improving patient outcomes.",[88,27],"MASLD",[90,91,92,93,94,95,96],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Advanced Liver Fibrosis","Primary Care Providers","Explainable AI","Provider-Level Crossover Trial","Simulation-Based Clinical Trial","Pilot Study","2025-12-12",{"date":99,"type":35},"2025-12-26",{"date":101,"type":20},"2026-06-15",{"date":103,"type":20},"2027-06-15",{"name":105,"class":42},"Yale University",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":43},"100225016","establishment-of-nafld-cohort-and-development-of-fibrosis-markers-100225016","NCT02206841","Establishment of NAFLD Cohort and Development of Fibrosis Markers","Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis","NAFLD","Inclusion Criteria:\n\n* Patients with histologically confirmed fatty liver disease\n* Patients with radiologically confirmed fatty liver disease\n\nExclusion Criteria:\n\n* History of significant alcohol consumption\n* Viral hepatitis\n* Autoimmune hepatitis\n* Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)\n* Hepatotoxic medication (e.g. amiodarone)",{"count":115,"type":20},1000,"3 Years","OBSERVATIONAL","This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.",[27],[30,121],"markers","2025-05-12",{"date":124,"type":35},"2025-05-15",{"date":126,"type":4},"2014-01-01",{"date":128,"type":20},"2030-12-31",{"name":130,"class":42},"Seoul National University Boramae Hospital"]